Cas:941294-18-4 3-Bromo-N-cyclopentyl-5-nitrobenzamide manufacturer & supplier

Chemical Name:3-Bromo-N-cyclopentyl-5-nitrobenzamide

CAS.NO:941294-18-4

Synonyms:N-Cyclopentyl 3-bromo-5-nitrobenzamide

Molecular Formula:C₁₂H₁₃BrN₂O₃

Molecular Weight:313.14700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:74.92000

Exact Mass:312.01100

LogP:3.94380

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-Cyclopentyl 3-bromo-5-nitrobenzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Cyclopentyl 3-bromo-5-nitrobenzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Cyclopentyl 3-bromo-5-nitrobenzamide Use and application,N-Cyclopentyl 3-bromo-5-nitrobenzamide technical grade,usp/ep/jp grade.

Related News: Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. 3-Bromo-N-cyclopentyl-5-nitrobenzamide manufacturer At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves. 3-Bromo-N-cyclopentyl-5-nitrobenzamide supplier Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. 3-Bromo-N-cyclopentyl-5-nitrobenzamide vendor It was not clear which inquiry – the company’s or the government’s – was launched first and to what extent the subjects coincide. However, as Reuters reported last month, based on three sources familiar with the matter, the Justice Department’s investigation into Lilly includes a review of alleged manufacturing irregularities and records-tampering. 3-Bromo-N-cyclopentyl-5-nitrobenzamide factory Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue.